Trials / Completed
CompletedNCT03760198
Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 220 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is intented to evaluate the efficacy and safety of MEDITOXIN compared to placebo in treatment of primary axillary hyperhidrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Meditoxin | 50U of MEDITOXIN is injected intradermally to each axilla |
| OTHER | Placebo | normal saline is injected intradermally to each axilla |
Timeline
- Start date
- 2018-08-03
- Primary completion
- 2019-07-03
- Completion
- 2019-09-17
- First posted
- 2018-11-30
- Last updated
- 2020-07-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03760198. Inclusion in this directory is not an endorsement.